Wednesday, 26 August 2026European Markets

AUGROS COSMETICS Stock Bearish Momentum With A 13% Fall So Far Today

Loading stream...

(vianews) - shares of augros cosmetics (cac 40: augr.pa) dropped by a staggering 13.75% to €6.90 at 14:40 est on friday, following the last session's upward trend. cac 40 is jumping 1.27% to €7,227.84, following the last session's upward trend. this seems, up until now, an all-around up trend exchanging session today.

about augros cosmetics

augros cosmetic packaging sa provides customized packaging solutions in france. the company offers decoration solutions for glass, plastic, and aluminum packaging materials. it serves the perfume, cosmetic, and spirit industries. the company is based in alencon, france. augros cosmetic packaging sa operates as a subsidiary of famille bourgine.

earnings per share

as for profitability, augros cosmetics has a trailing twelve months eps of €0.43.

pe ratio

augros cosmetics has a trailing twelve months price to earnings ratio of 16.05. meaning, the purchaser of the share is investing €16.05 for every euro of annual earnings.

volatility

augros cosmetics's last week, last month's, and last quarter's current intraday variation average was 10.99%, 3.03%, and 7.44%.

augros cosmetics's highest amplitude of average volatility was 10.99% (last week), 11.81% (last month), and 7.44% (last quarter).

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com